AFib affects around 8 million Europeans over the age of 65, and this figure is anticipated to grow over the next 30 years.
In order to help hemophiliacs regain hemostasis, Qfitlia helps boost thrombin production by decreasing AT, a protein that prevents blood clotting.
Eli Lilly and Company’s (LLY) donanemab is not recommended for marketing authorization for the treatment of early symptomatic Alzheimer’s disease, according to an opinion released [Read More…]
For the clinical phase, Bayer has acquired the sole global license for an MTA-cooperative PRMT5 inhibitor that targets MTAP-deleted tumors selectively.
Approval based on data from the pivotal phase III EAGLE-2 and EAGLE-3 trials.
articipants receiving sozinibercept combination therapy with a dosing regimen of every four weeks or every eight weeks.
In addition to being the first to examine the safety and effectiveness of an automated insulin delivery (AID) system in conjunction with an Abbott FreeStyle Libre® 2 family sensor
Mounjaro, the First and Only GIP and GLP-1 Receptor Agonist Approved for Type 2 Diabetes.
The findings support the increasing amount of data showing that N6LS is a strong antiviral that may be used as part of an all-encompassing antiretroviral treatment plan.
Trial continues as planned to 52 weeks to further characterize the risk-benefit profile.
